Japan thumps Pfizer for missing 200 side effect reports; Caraco should have warned plant workers of job loss, court says;

@FiercePharma: Academic docs and biotechs partner with veterinarians to find cancer cures. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: Can Sprout's Addyi shrug off serious side effects? These blockbusters did. FiercePharmaMarketing article | Follow @CarlyHFierce

> Pfizer ($PFE) is under fire at Japan's health ministry, which says the U.S.-based multinational failed to report about 200 cases of serious side effects, including 6 deaths, over a 6-year period ending in 2014. Report

> Caraco Pharmaceutical, a U.S. subsidiary of India's Sun Pharma, was still required to give notice to production workers that they'd be laid off, even after the manufacturer was raided by U.S. regulators, a court found. Report

> India's Dr. Reddy's Laboratories ($RDY) is reshuffling its top management after the departure of its North American chief, Umang Vora. Report

> South Africa-based Adcock Ingram plans to sell off an underperforming Indian unit, Cosme Farm Laboratories, after two years of writedowns. Report

> Slovenia-based drugmaker Krka saw profits climb 5% for the second quarter as strong sales in Western Europe made up for weaker performance in Russia. Report

> Two workers at a Gedeon Richter plant in Budapest were injured in an explosion. Report

Medical Device News

@FierceMedDev: Israeli nitric oxide drug-device player files for up to $36M Nasdaq IPO. Article | Follow @FierceMedDev

@VarunSaxena2: Providence Medical receives $12M in financing to expand sales of its spinal fusion devices. Story | Follow @VarunSaxena2

@EmilyWFierce: Recipharm strikes development deal for RedHill's bacteria-fighter candidate. FierceCRO item | Follow @EmilyWFierce

> Greatbatch grabs Lake Regional Medical for $730M to expand surgical offerings. News

> Abbott denies FT report that it's preparing $25B bid for St. Jude Medical. Article

Biotech News

@FierceBiotech: UCSF cardiology chief builds a case for two new targets for heart drugs. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: I'm happy to see $MDVN back in a late-stage development race. It's been awhile, and they're smart, aggressive players. More from FiercePharmaMarketing | Follow @JohnCFierce

> J&J positions blockbuster contender daratumumab for a multiple myeloma showdown. Report

> Repatha OK looming, analysts wait to see if Amgen will start PCSK9 price war. More

> Novo Nordisk defers dream of expanding Victoza label after PhIII falls short. Story

> MorphoSys trades assets with Immatics to bolster I-O ambitions. Article

Vaccines News

> Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials. News

> Valneva licenses EB66 technology to develop human, veterinary vaccines. Report

> Takeda expands vaccine platform rights with Nanotherapeutics agreement. More

> FluGen reels in $12M to fund PhI of its universal flu jab. Story

> Scripps Research Institute, J&J test 'universal' flu vaccine in mice, monkeys. Article

CRO News

> WuXi inks lab testing pact with Chinese Lee's Pharm. News

> Germany lists 54 GVK suspensions as EU comes down on Indian CRO. More

> Recipharm strikes development deal for RedHill's bacteria-fighter candidate. Report

> CRO field to grow nearly 10% annually through 2019, report says. Story

> India's Accutest Research Labs expands into Latin America. Article

Pharma Manufacturing News

> Shire works deal with Sanquin so it can boost production of rare disease drug. More

> Woodcock says FDA will keep new plant quality grades a secret. Report

> Sterilization specialist on expansion streak. Item

> Sucampo gets control of Amitiza production in deal for Japanese company. Story

> Novo picks Clayton, NC, for its first U.S. API plant. Article

Pharma Asia News

> India's Gujarat state moves closer to country's first medical device testing lab. Story

> China's Shenzhen Hepalink keeps N. American deal stream rolling with Cytovance. More

> Oncology trials in China may see pilot program for 60-day IND decision. Story

> BD Life Science buys Silicon Valley-based Cellular Research, part of Decheng portfolio. Article

> Japan's PAFSC to review application from Takeda on glatiramer this week. Item

And Finally... Johnson & Johnson ($JNJ) sold off its Splenda brand sweetener as part of its ongoing strategy to focus in on key consumer health product lines. Report